natgillin/translations-raw huggingface dataset:
To differentiate between elevations in transaminases due to response to treatment and increases potentially related to lactic acidosis, physicians should ensure that changes in ALT are associated with improvements in other laboratory markers of chronic hepatitis B.
Da bi razlikovali med zvišanjem vrednosti transaminaz zaradi odziva na zdravljenje in zvišanjem zaradi potencialne povezanosti z laktacidozo, bi morali zdravniki preveriti, če so spremembe vrednosti ALT združene z izboljšanjem drugih laboratorijskih označevalcev kroničnega hepatitisa B.
Co-infection with hepatitis C or D: There are no data on the efficacy of adefovir dipivoxil in patients co-infected with hepatitis C or hepatitis D.
Sočasna okužba z hepatitisom C ali D: Ni podatkov o učinkovitosti dipivoksiladefovirata pri bolnikih sočasno okuženih s hepatitisom C ali hepatitisom D.
Nephrotoxicity was observed in animals at systemic exposures at least 3-10 times higher than those achieved in humans at the recommended therapeutic dose of 10 mg/day.
Nefrotoksičnost je bila opažena pri živalih pri sistemski izpostavljenosti, ki je bila najmanj 3 do 10 krat višja od dosežene izpostavljenosti pri človeku ob priporočenem terapevtskem odmerku 10 mg na dan.
As far as possible, treatment of hepatitis B by adefovir dipivoxil in an HIV co-infected patient should be reserved for patients whose HIV RNA is controlled.
Kolikor je mogoče, naj bi bilo zdravljenje hepatitisa B z dipivoksiladefoviratom pri bolnikih sočasno okuženih s HIV omejeno na bolnike s kontrolirano vrednostjo HIV RNA.
• If you do miss a dose of Hepsera, take it as soon as you can, and then take your next scheduled dose at its regular time.
• Če pozabite vzeti odmerek zdravila Hepsera, ga vzemite čim prej in nadaljujte po običajnem urniku odmerjanja.
If overdose occurs, the patient must be monitored for evidence of toxicity, and standard supportive treatment applied as necessary.
V primeru prevelikega odmerka je potrebno pri bolniku nadzorovati znake toksičnosti in mu nuditi standardno podporno zdravljenje.
Median Cmax and AUC0-∞ values were 16.70 (9.66-30.56) ng/ml and 204.40 (109.75-356.05) ng·h/ml, respectively.
Mediana Cmax je bila 16,70 (9,66-30,56) ng/ml in mediana AUC0-∞ 204,40 (109,75-356,05) ng·h/ml.
Furthermore, for the few patients who remained on drug at week 240 (n=12) BMI Z score was lower than typical for their age and gender.
Za nekaj bolnikov, ki so se v 240. tednu še vedno zdravili z zdravilom (n=12), so bile z-vrednosti indeksa telesne mase nižje, kot je običajno za njihovo starost in spol.
Hepsera 10 mg tablets are round, white to off-white tablets.
Tablete Hepsera 10 mg so okrogle, bele do skoraj bele tablete.
- In HBeAg positive patients without cirrhosis, treatment should be administered for at least 6-12 months after HBe seroconversion (HBeAg loss and HBV DNA loss with anti-HBe detection) is confirmed or until HBs seroconversion or there is loss of efficacy (see section 4.4).
- Pri HBeAg pozitivnih bolnikih brez ciroze naj zdravljenje traja najmanj 6-12 mesecev po potrditvi HBe serokonverzije (izguba HBeAg in izguba HBV DNA z detekcijo anti-HBe) ali do HBs serokonverzije ali dokler ne pride do izgube učinkovitosti (glejte poglavje 4.4).
There are no data on the effect of adefovir dipivoxil on transmission of HBV from mother to infant.
Ni podatkov o tem kako dipivoksiladefovirat vpliva na prenos HBV z matere na otroka.
Elevations in serum ALT that occurred in patients with compensated liver function treated with 10 mg adefovir dipivoxil were not accompanied by clinical and laboratory changes associated with liver decompensation.
Dvigov vrednosti serumske ALT, ki so se pojavili pri bolnikih s kompenzirano jetrno funkcijo, zdravljenih z 10 mg dipivoksiladefovirata, niso spremljale klinične in laboratorijske spremembe povezane z jetrno dekompenzacijo.
Adefovir was not mutagenic in microbial mutagenicity assays involving Salmonella typhimurium (Ames) and Escherichia coli in the presence and absence of metabolic activation.
Adefovir ni bil mutagen pri preizkusih mutagenosti na mikrobih, ki so vključevali Salmonelo tifimurium (Ames) in Escherichia coli v prisotnosti ali odsotnosti presnovne aktivacije.
The following pack sizes are available: outer cartons containing 1 bottle of 30 tablets and outer cartons containing 90 (3 bottles of 30) tablets.
Na voljo so naslednje velikosti pakiranj: škatle z 1 plastenko s po 30 tabletami in škatle s po 90 (3 plastenke po 30) tabletami.
A clinical study in liver-transplant patients has shown that no pharmacokinetic interaction occurs when adefovir dipivoxil 10 mg once daily is administered concomitantly with tacrolimus, an immunosuppressant which is predominantly metabolised via the CYP450 system.
Klinična študija pri bolnikih s transplantacijo jeter je pokazala, da ne pride do farmakokinetičnega medsebojnega delovanja pri sočasnem jemanju dipivoksiladefovirata 10 mg enkrat na dan s takrolimusom, imunosupresivom, ki se pretežno presnavlja prek sistema CYP450.
In the HBeAg positive study, treatment beyond 48 weeks resulted in further reductions in serum HBV DNA levels and increases in the proportion of patients with ALT normalisation, HBeAg loss and seroconversion.
V študiji s HBeAg pozitivnimi bolniki je zdravljenje daljše od 48 tednov povzročilo nadaljnje znižanje vrednosti serumske HBV DNA in povečanje deleža bolnikov z normalizacijo vrednosti ALT, izgubo HBeAg in serokonverzijo.
It is recommended to administer adefovir dipivoxil (one 10 mg tablet) every 48 hours in these patients.
Tem bolnikom je priporočeno dajati dipivoksiladefovirat (eno 10-miligramsko tableto) vsakih 48 ur.
Patients with advanced liver disease or cirrhosis may be at a higher risk for hepatic decompensation following hepatitis exacerbation which may be fatal.
Bolniki z napredovalo boleznijo jeter ali cirozo so lahko bolj izpostavljeni tveganju za jetrno dekompenzacijo, ki sledi poslabšanju hepatitisa in je lahko smrtna.
To date there is no evidence that daily dosing with 10 mg adefovir dipivoxil results in emergence of adefovir-associated resistance mutations in the HIV reverse transcriptase.
Za sedaj ni dokazov da bi dnevni odmerek 10 mg dipivoksiladefovirata povzročil nastanek mutacije za rezistenco povezane z adefovirjem v HIV reverzni transkriptazi.
Hepatic impairment: Pharmacokinetic properties were similar in patients with moderate and severe hepatic impairment compared to healthy volunteers (see section 4.2).
Motnje v delovanju jeter: Farmakokinetične lastnosti so bile podobne pri bolnikih z zmernimi do resnimi motnjami v delovanju jeter in pri zdravih prostovoljcih (glejte poglavje 4.2).
Paediatric population: Hepsera is not recommended for use in children below the age of 18 years due to limitations of the available data on safety and efficacy (see section 5.1).
Pediatrična populacija: Uporaba zdravila Hepsera pri otrocih, starih do 18 let, ni priporočljiva, ker so podatki o varnosti in učinkovitosti omejeni (glejte poglavje 5.1).
If you are lactose-intolerant, or if you have been told that you have an intolerance to some sugars, talk to your doctor before taking Hepsera.
Če ne prenašate laktoze ali če so vam povedali, da ne prenašate nekaterih sladkorjev, se pred jemanjem zdravila Hepsera posvetujte z zdravnikom.
Adults: The recommended dose of Hepsera is 10 mg (one tablet) once daily taken orally with or without food.
Odrasli: Priporočeni odmerek Hepsere je 10 mg (ena tableta) enkrat na dan, peroralno z ali brez hrane.
In these clinical studies patients had active viral replication (HBV DNA ≥ 100,000 copies/ml) and elevated ALT levels (≥ 1.2 x Upper Limit of Normal (ULN)).
V teh kliničnih študijah so imeli bolniki aktivno virološko replikacijo (HBV DNA ≥ 100.000 kopij/ml) in povišane vrednosti ALT (≥ 1,2 krat zgornja referenčna vrednost (ULN, Upper Limit of Normal)).
What you need to know before you take Hepsera Do not take Hepsera
Kaj morate vedeti, preden boste vzeli zdravilo Hepsera Ne jemljite zdravila Hepsera:
Hepsera is indicated for the treatment of chronic hepatitis B in adults with:
Zdravilo Hepsera je indicirano za zdravljenje kroničnega hepatitisa B pri odraslih s:
At week 96, patients continuing on adefovir dipivoxil 10 mg had sustained suppression of serum HBV with maintenance of the reduction seen at week 48.
V 96. tednu so imeli bolniki, ki so nadaljevali z jemanjem 10 mg dipivoksiladefovirata, stalno supresijo serumskega HBV z ohranitvijo znižanja, kakršno je bilo vidno v 48. tednu.
If treatment cessation is necessary, patients should be closely monitored for several months after stopping treatment as exacerbations of hepatitis have occurred after discontinuation of 10 mg adefovir dipivoxil.
Če je potrebno prenehanje zdravljenja, morajo biti bolniki še nekaj mesecev po ukinitvi zdravljenja skrbno nadzorovani, saj so se po prekinitvi uporabe 10 mg dipivoksiladefovirata pojavila poslabšanja hepatitisa.
White to off-white, round, flat-faced, bevelled-edge tablets, 7 mm in diameter, debossed with “GILEAD” and “10” on one side and a stylised shape of a liver on the other side.
Bele do skoraj bele, okrogle, ploščate tablete z zabrušenim robom, 7 mm premera, z vtisnjenima znakoma “GILEAD” in “10” na eni strani ter stilizirano obliko jeter na drugi strani.
In patients with compensated liver disease, these increases in serum ALT are generally not accompanied by an increase in serum bilirubin concentrations or hepatic decompensation (see section 4.8).
Pri bolnikih s kompenzirano boleznijo jeter povišanje vrednosti serumske ALT na splošno ne spremlja zvišanje koncentracij serumskega bilirubina ali jetrna dekompenzacija (glejte poglavje 4.8).
• lamivudine-resistant HBV with either compensated or decompensated liver disease, including patients pre- and post-liver transplantation or co-infected with HIV.
• na lamivudin odpornim HBV s kompenzirano oziroma dekompenzirano boleznijo jeter vštevši bolnike pred in po transplantaciji jeter oziroma bolnike sočasno okužene s HIV.
Safety in patients with decompensated disease:
Varnost pri bolnikih z dekompenzirano boleznijo jeter:
Adefovir diphosphate inhibits viral polymerases by competing for direct binding with the natural substrate (deoxyadenosine triphosphate) and, after incorporation into viral DNA, causes DNA chain termination.
Adefovir difosfat zavira polimeraze virusov s kompeticijo za direktno vezavo z naravnim substratom (dezoksiadenozin trifosfat) in po vgraditvi v virusno DNA povzroči prekinitev njene sinteze.
Severe cases, sometimes with fatal outcome, were associated with pancreatitis, liver failure/hepatic steatosis, renal failure and higher levels of serum lactate.
Resni primeri, včasih s smrtnim izidom, so bili povezani s pankreatitisom, jetrno odpovedjo/jetrno steatozo, ledvično odpovedjo in višjimi vrednostmi serumskega laktata.
• decompensated liver disease in combination with a second agent without cross-resistance to Hepsera.
• dekompenzirano boleznijo jeter v kombinaciji z drugo učinkovino, ki ni navzkrižno rezistentna na zdravilo Hepsera.
• If you are sick (vomit) less than 1 hour after taking Hepsera take another tablet.
• Če bruhate manj kot eno uro po jemanju zdravila Hepsera, vzemite drugo tableto.
These exacerbations occurred in the absence of HBeAg seroconversion and presented as serum ALT elevations and increases in serum HBV DNA.
Ta poslabšanja so se pojavila v odsotnosti HBeAg serokonverzije in so se pokazala kot dvig serumske ALT in povišanje serumske HBV DNA.
In addition, the long-term (4 to 5 years) development of resistance to adefovir dipivoxil was significantly lower in patients who had serum HBV DNA below the limit of quantification (< 1,000 copies/ml) at week 48 as compared to patients with serum HBV DNA above 1,000 copies/ml at week 48.
Poleg tega je bil dolgoročni (4 do 5 let) razvoj rezistence proti dipivoksiladefoviratu značilno nižji pri bolnikih, ki so imeli serumsko HBV DNA pod mejo količinske zaznave (< 1.000 kopij/ml) v 48. tednu, v primerjavi z bolniki s serumsko HBV DNA nad 1.000 kopij/ml v 48. tednu.
It is recommended that the dosing interval of 10 mg adefovir dipivoxil is modified in patients with creatinine clearance between 30 and 49 ml/min.
Priporoča se prilagoditi interval med odmerki 10 mg dipivoksiladefovirata pri bolnikih z očistkom kreatinina od 30 do 49 ml/min.
Depending on the results, your doctor may change how often you take Hepsera.
Na podlagi rezultatov teh preiskav bo morda zdravnik spremenil pogostnost jemanja zdravila Hepsera.
- In HBeAg negative patients without cirrhosis, treatment should be administered at least until HBs seroconversion or there is evidence of loss of efficacy.
- Pri HBeAg negativnih bolnikih brez ciroze naj zdravljenje traja najmanj do HBs serokonverzije ali do dokazane izgube učinkovitosti.
Higher doses must not be administered.
Ne sme se jemati višjih odmerkov od predpisanih.
Patients who completed the first 96 weeks of the HBeAg negative study and received adefovir dipivoxil treatment during weeks 49 to 96, were offered the opportunity to receive open-label treatment with adefovir dipivoxil from study week 97 through to week 240.
Bolnikom, ki so zaključili prvih 96 tednov študije s HBeAg negativnimi bolniki in so prejemali zdravljenje z dipivoksiladefoviratom med 49. in 96. tednom, so ponudili možnost prejemanja odprtega zdravljenja z dipivoksiladefoviratom od 97. študijskega tedna do 240. tedna.
Pharmacokinetic studies were principally conducted in Caucasian patients.
Farmakokinetične raziskave so bile v glavnem izpeljane pri belcih.
The silica gel desiccant is contained in either a separate sachet or a small canister and should not be swallowed.
Sušilno sredstvo iz silikagela je bodisi v posebni vrečki, bodisi v majhni plastenki, in ga ne smete pogoltniti.
Administration of 500 mg adefovir dipivoxil daily for 2 weeks and 250 mg daily for 12 weeks has been associated with the gastrointestinal disorders listed above and anorexia.
Jemanje 500 mg dipivoksiladefovirata na dan 2 tedna in 250 mg na dan 12 tednov so spremljale zgoraj navedene bolezni prebavil in anoreksija.
Long-term safety data in patients with compensated disease:
Dolgoročna študija varnosti pri bolnikih s kompenzirano boleznijo jeter:
Systemic exposure to adefovir was not affected when 10 mg adefovir dipivoxil was taken with a high fat meal.
Sistemska izpostavljenost adefovirju ni bila spremenjena, ko je bil 10 mg dipivoksiladefovirata vzet ob z maščobami bogatem obroku.
They are the same as some of the common side effects of Hepsera.
Ti simptomi so enaki kot nekateri pogosti neželeni učinki zdravila Hepsera.
Baseline Creatinine Clearance (ml/min)
Začetna vrednost očistka kreatinina (ml/min)
In a long-term safety study of 65 HBeAg positive patients with compensated liver disease (after a median exposure of 234 weeks), 6 patients (9 %) had confirmed increases in serum creatinine of at least 0.5 mg/dl from baseline with 2 patients discontinuing from the study due to the elevated serum creatinine concentration.
V dolgoročni študiji varnosti s 65 HBeAg pozitivnimi bolniki s kompenzirano boleznijo jeter (po mediani izpostavljenosti 234 tednov) je bilo pri 6 bolnikih (9%) potrjeno povečanje serumskega kreatinina za vsaj 0,5 mg/dl od začetne vrednosti, dva bolnika pa sta prekinila študijo zaradi povečane koncentracije serumskega kreatinina.
Studies in orally dosed animals do not indicate teratogenic or foetotoxic effects.
Študije na živalih, ki so prejemale odmerke oralno, ne kažejo na teratogenost ali toksične učinke na zarodkih.
The primary dose-limiting toxic effect associated with administration of adefovir dipivoxil in animals (mice, rats and monkeys) was renal tubular nephropathy characterised by histological alterations and/or increases in blood urea nitrogen and serum creatinine.
Najpomembnejši dozo omejujoč toksičen vpliv, povezan z vnosom dipivoksiladefovirata pri živalih (miših, podganah in opicah), je ledvična tubularna nefropatija, ki jo označujejo histološke spremembe in/ali zvišanje dušika v sečnini v krvi in zvišanje serumskega kreatinina.
No effects on male or female fertility, or reproductive performance, occurred in rats and there was no embryotoxicity or teratogenicity in rats or rabbits administered adefovir dipivoxil orally.
Pri podganah ni bilo opaženega vpliva na plodnost moških in žensk oziroma na reprodukcijsko sposobnost in prav tako ni prišlo do embriotoksičnosti oziroma teratogenosti pri podganah oziroma zajcih, ki so dobivali dipivoksiladefovirat oralno.
Resistance: Resistance to adefovir dipivoxil (see section 5.1) can result in viral load rebound which may result in exacerbation of hepatitis B and, in the setting of diminished hepatic function, lead to liver decompensation and possible fatal outcome.
Odpornost: Odpornost na dipivoksiladefovirat (glejte poglavje 5.1) lahko povzroči povratni odziv virusne obremenitve, kar lahko nadalje povzroči poslabšanje hepatitisa B, ob poslabšanem jetrnem delovanju pa tudi dekompenzijo jeter in morebitni smrtni izid.
The elimination of adefovir by peritoneal dialysis has not been studied.
Odstranjevanje adefovirja preko peritonealne dialize ni raziskano.
The demonstration of the benefit of adefovir dipivoxil is based on histological, virological, biochemical, and serological responses in adults with:
Dokaz koristnostni dipivoksiladefovirata sloni na histoloških, viroloških, biokemičnih in seroloških odgovorih pri odraslih s:
Serum HBV DNA levels remained undetectable and ALT levels normalised in approximately two thirds of patients following treatment with adefovir dipivoxil for up to 240 weeks.
HBV DNA so ostale nezaznavne in vrednosti ALT so se normalizirale pri približno dveh tretjinah bolnikov po zdravljenju z dipivoksiladefoviratom do 240. tedna.
Preliminary clinical data suggest the adefovir-associated resistance mutation rtA181V may confer a reduced susceptibility to lamivudine, and the lamivudine-associated mutation rtA181T may confer a reduced susceptibility to adefovir dipivoxil.
Preliminarni klinični podatki kažejo, da mutacija rtA181V, povezana z rezistenco proti adefovirju, lahko povzroči zmanjšano občutljivost za lamivudin, in da mutacija rtA181T, povezana z lamivudinom, lahko povzroči zmanjšano občutljivost za dipivoksiladefovirat.
Based on the results of these in vitro experiments and the known elimination pathway of adefovir, the potential for CYP450 mediated interactions involving adefovir with other medicinal products is low.
Na podlagi rezultatov teh in vitro poskusov in glede na znano pot izločanja adefovirja je možnost za s CYP450 posredovane interakcije adefovirja z drugimi zdravili majhna.
Patients receiving medicinal products that may affect renal function: Adefovir dipivoxil should not be administered concurrently with tenofovir disoproxil fumarate (Viread).
Bolniki, ki prejemajo zdravila, ki lahko vplivajo na ledvično funkcijo: Dipivoksiladefovirata se ne sme jemati sočasno s dizoproksiltenofoviratom fumaratom (Viread).
Skin and subcutaneous tissue disorders: Common:
Bolezni kože in podkožja: Pogosto:
Studies in animals administered adefovir intravenously have shown reproductive toxicity (see section 5.3).
Študije na živalih, ki so jim adefovir dajali intravenozno, so pokazale vpliv na sposobnost razmnoževanja (glejte poglavje 5.3).
No dosing interval recommendations are available for other dialysis patients (e.g. ambulatory peritoneal dialysis patients) or non-haemodialysed patients with creatinine clearance less than 10 ml/min.
Priporočil za intervale med odmerki za druge bolnike na dializi (npr. bolnike na ambulantni peritonealni dializi) ali bolnike, ki niso na hemodializi, imajo pa očistek kreatinina manjši od 10 ml/min, ni.
Clinical and laboratory evidence of exacerbations of hepatitis have occurred after discontinuation of treatment with 10 mg adefovir dipivoxil (see section 4.4).
Klinični in laboratorijski dokazi poslabšanja hepatitisa so se pojavili po prekinitvi zdravljenja z 10 mg dipivoksiladefovirata (glejte poglavje 4.4).
Contains lactose monohydrate, see package leaflet for further information.
SEZNAM POMOŽNIH SNOVI Vsebuje laktozo monohidrat, za dodatne informacije glejte navodilo za uporabo.
The volume of distribution at steady-state following intravenous administration of 1.0 or 3.0 mg/kg/day is 392±75 and 352±9 ml/kg, respectively.
Volumen porazdelitve v stanju dinamičnega ravnotežja (steady-state) po intravenskemu vnosu 1,0 mg/kg/dan je 392 ± 75 ml/kg oziroma po intravenskem vnosu 3,0 mg/kg/dan je 352 ± 9 ml/kg.
Adefovir dipivoxil should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus.
Dipivoksiladefovirat se sme uporabljati v nosečnosti samo v primeru, kadar pričakovana korist upravičuje potencialno tveganje za plod.
Distribution: Preclinical studies show that after oral administration of adefovir dipivoxil, adefovir is distributed to most tissues with the highest concentrations occurring in kidney, liver and intestinal tissues.
Porazdelitev: Predklinične raziskave so pokazale, da se po peroralnem vnosu dipivoksiladefovirata, adefovir porazdeli po večini tkiv z najvišjo koncentracijo doseženo v ledvicah, jetrih in tkivu prebavil.
At week 48, in children aged 2 to 11 years old, no statistically significant difference was observed in the proportions of patients that achieved the primary endpoint of serum HBV DNA < 1,000 copies/ml and normal ALT levels between the placebo arm and the adefovir dipivoxil arm.
V 48. tednu pri otrocih, starih od 2 do 11 let, niso opazili statistično pomembne razlike v deležu bolnikov, ki so dosegli primarni cilj serumske HBV DNA < 1.000 kopij/ml in normalne vrednosti ALT med skupino, ki je prejemala placebo in skupino, ki je prejemala dipivoksiladefovirat.
Therefore, clinical response to treatment and renal function should be closely monitored in these patients (see section 4.4).
Zato je potrebno pri teh bolnikih skrbno nadzorovati klinični odziv na zdravljenje in ledvično funkcijo (glejte poglavje 4.4).
Moreover, to emphasize that the frequency is more driven by the more common event proximal renal tubulopathy, the terms are combined as follows “Proximal renal tubulopathy (including Fanconi syndrome)” rather the two terms separated.
Da bi poudarili, da je pogostnost opredeljena bolj na osnovi bolj pogostega dogodka proksimalne ledvične tubulopatije, sta izraza združena na naslednji način: “Proksimalna ledvična tubulopatija (vključno s Fanconijevim sindromom)”, in nista več zapisana ločeno.
Paediatric population: The pharmacokinetics of adefovir dipivoxil were studied in an efficacy and safety study of a daily dose of 0.25 mg/kg to 10 mg adefovir dipivoxil in children (aged 2 to < 18 years).
Pediatrična populacija: Farmakokinetične lastnosti dipivoksiladefovirata so proučevali v študiji učinkovitosti in varnosti z dnevnim odmerkom 0,25 mg/kg do 10 mg dipivoksiladefovirata pri otrocih (starih od 2 do < 18 let).
{MM/YYYY}
NN: {številka}
A pharmacokinetic interaction between adefovir and the immunosuppressant, cyclosporin, is also considered unlikely as cyclosporin shares the same metabolic pathway as tacrolimus.
Farmakokinetično medsebojno delovanje med adefovirjem in imunosupresivom, ciklosporinom, prav tako ni verjetno, ker ima ciklosporin isto presnovno pot kot takrolimus.
However, 4 patients who discontinued lamivudine treatment developed the rtN236T mutation while receiving adefovir dipivoxil monotherapy and all experienced serum HBV rebound.
Vendar pa so 4 bolniki, ki so prekinili zdravljenje z lamivudinom, razvili mutacijo rtN236T med monoterapijo z dipivoksiladefoviratom in vsi so izkusili rebound vrednosti serumske HBV.
Hepsera is used to treat chronic hepatitis B, an infection with hepatitis B virus (HBV), in adults.
Zdravilo Hepsera se uporablja za zdravljenje kronične okužbe z virusom hepatitisa B (HBV) pri odraslih.
Virological response should be closely monitored in patients treated with adefovir dipivoxil, with HBV DNA measured every 3 months.
Pri bolnikih, ki se zdravijo z dipivoksiladefoviratom, je treba skrbno spremljati virološki odziv, pri čemer je treba vrednost HBV DNA meriti vsake tri mesece.